©2024 Stanford Medicine
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Not Recruiting
Trial ID: NCT03391778
Purpose
This trial will evaluate long term safety of participants who have received GlaxoSmithKline
(GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Official Title
Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies
Stanford Investigator(s)
Kristen N Ganjoo
Professor of Medicine (Oncology)
Eligibility
Inclusion Criteria:
- Participants who have received at least one dose of GSK adoptive cell therapy agent.
- Participants who have completed GSK sponsored or supported interventional study or
have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive
cell therapy.
- Contraceptive use by men or women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Exclusion Criteria:
- None
Intervention(s):
biological: GSK adoptive cell therapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ileana Aguilar Torres
650-724-1388